Uncategorized - malecare.org

Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) in men with metastatic castrate resistant prostate cancer (mCRPC). This rational for conducting this trial is the lack of cross [...]

By Malecare|2020-02-04T10:12:06-05:00May 16th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, immunotherapy, Provenge, Uncategorized, vaccines, Xtandi|0 Comments

Startling Fact: PSA Testing Frequency Changes PSA Doubling Time – A Time Honored Surrogate Biomarker is Not Valid!

In our quest to understand our prostate cancer we have developed many “measures” of our disease aggressiveness and progression. Many of these measures are generally accepted has valid, but many have never been validated. One example is the prognostic nature of PSA Doubling Time (PSADT) in men with biochemically recurrent prostate cancer (BRPC or PSA [...]

By Malecare|2020-02-04T11:55:32-05:00May 15th, 2014|Advanced Prostate Cancer, Bio Chemical Recurrence, biomarkers, Drugs & Treatments, PSA, PSADT, Research, Start A Cure, supplements, Uncategorized, Understanding APC|1 Comment

NICE Rejects Zytiga for Men Without Chemotherapy Exposure

The National Institute for Health and Care Excellence (NICE), which is Britain’s healthcare cost-effectiveness agency, has determined that abiraterone (Zytiga) was not worth giving to men with castrate resistant metastatic prostate cancer who have yet to had chemotherapy. Unlike the FDA in the United States which rules only on a drug’s efficacy, NICE decides if [...]

By Malecare|2014-05-14T10:53:53-04:00May 14th, 2014|Advanced Prostate Cancer, General Information, NICE, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|4 Comments

Statins Might Inhibit Prostate Cancer from Invading Bones

One of the more recent conversations surrounding prostate cancer treatment that we have been hearing involves the use of the anti-cholesterol drugs or statins. The conversation, whether or not statins might be a good treatment option for men with both localized disease and as an alternative to hormone treatment (ADT) for men with advanced prostate [...]

By Malecare|2017-10-19T10:48:21-04:00May 13th, 2014|Advanced Prostate Cancer, Bone Metastases, Drugs & Treatments, Metastases, On The Horizon, Research, Uncategorized, Understanding APC|0 Comments

A Surprising Biochemical Response to Ketoconazole In Post-Chemotherapy mCRPC Men When Compared to the Zytiga Trial Results

It has always been assumed that Ketoconazole, when used for the treatment of men with metastatic castration resistant prostate cancer (mCRPC), would not be as potent as abiraterone (Zytiga), but there has never been any head to head comparison to demonstrate this assumption! Ketoconazole is a less potent inhibitor of the CYP-17 enzyme, the mode [...]

By Malecare|2014-05-12T17:10:17-04:00May 12th, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, ketoconazole, Uncategorized, Understanding APC, Zytiga|0 Comments